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Abstract 
The relative function of the P2X7 receptor, an ATP-gated ion channel, varies between humans due to 
polymorphisms in the P2RX7 gene. This study aimed to assess the functional impact of P2X7 variation in 
a random sample of the canine population. Blood and genomic DNA were obtained from 69 dogs 
selected as representatives of a cross section of different breeds. P2X7 function was determined by flow 
cytometric measurements of dye uptake and patch-clamp measurements of inward currents. P2X7 
expression was determined by immunoblotting and immunocytochemistry. Sequencing was used to 
identify P2RX7 gene polymorphisms. P2X7 was cloned from an English springer spaniel, and point 
mutations were introduced into this receptor by site-directed mutagenesis. The relative function of P2X7 
on monocytes varied between individual dogs. The canine P2RX7 gene encoded four missense 
polymorphisms: F103L and P452S, found in heterozygous and homozygous dosage, and R270C and 
R365Q, found only in heterozygous dosage. Moreover, R270C and R365Q were associated with the cocker 
spaniel and Labrador retriever, respectively. F103L, R270C, and R365Q but not P452S corresponded to 
decreased P2X7 function in monocytes but did not explain the majority of differences in P2X7 function 
between dogs, indicating that other factors contribute to this variability. Heterologous expression of site-
directed mutants of P2X7 in human embryonic kidney-293 cells indicated that the R270C mutant was 
nonfunctional, the F103L and R365Q mutants had partly reduced function, and the P452S mutant 
functioned normally. Taken together, these data highlight that a R270C polymorphism has major 
functional impact on canine P2X7. 
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ABSTRACT	  
The	  relative	  function	  of	  the	  P2X7	  receptor,	  an	  ATP-­‐gated	  ion	  channel,	  varies	  between	  humans	  
due	  to	  polymorphisms	  in	  the	  P2RX7	  gene.	  This	  study	  aimed	  to	  assess	  the	  functional	  impact	  of	  
P2X7	  variation	   in	  a	  random	  sample	  of	   the	  canine	  population.	  Blood	  and	  genomic	  DNA	  were	  
obtained	  from	  69	  dogs	  selected	  as	  representatives	  of	  a	  cross-­‐section	  of	  different	  breeds.	  P2X7	  
function	  was	  determined	  by	   flow	  cytometric	  measurements	  of	  dye	  uptake	  and	  patch-­‐clamp	  
measurements	  of	  inward	  currents.	  P2X7	  expression	  was	  determined	  by	  immunoblotting	  and	  
immunocytochemistry.	   Sequencing	   was	   used	   to	   identify	   P2RX7	   gene	   polymorphisms.	   P2X7	  
was	  cloned	  from	  an	  English	  Springer	  Spaniel	  and	  point	  mutations	  were	   introduced	  into	  this	  
receptor	   by	   site-­‐directed	   mutagenesis.	   The	   relative	   function	   of	   P2X7	   on	   monocytes	   varied	  
between	   individual	   dogs.	   The	   canine	   P2RX7	   gene	   encoded	   four	   missense	   polymorphisms:	  
F103L	  and	  P452S,	  found	  in	  heterozygous	  and	  homozygous	  dosage;	  R270C	  and	  R365Q,	  found	  
only	   in	  heterozygous	  dosage.	  Moreover,	  R270C	  and	  R365Q	  were	  associated	  with	  the	  Cocker	  
Spaniel	   and	   Labrador	   Retriever,	   respectively.	   F103L,	   R270C	   and	   R365Q	   but	   not	   P452S	  
corresponded	  to	  decreased	  P2X7	   function	   in	  monocytes,	  but	  did	  not	  explain	   the	  majority	  of	  
differences	   in	   P2X7	   function	   between	   dogs,	   indicating	   that	   other	   factors	   contribute	   to	   this	  
variability.	   Heterologous	   expression	   of	   site-­‐directed	  mutants	   of	   P2X7	   in	   human	   embryonic	  
kidney-­‐293	  cells	  indicated	  that	  the	  R270C	  mutant	  was	  non-­‐functional,	  the	  F103L	  and	  R365Q	  
mutants	   had	   partly	   reduced	   function,	   and	   the	   P452S	   mutant	   functioned	   normally.	   Taken	  
together,	   these	   data	   highlight	   that	   a	   R270C	   polymorphism	   has	  major	   functional	   impact	   on	  
canine	  P2X7.	  
	  
Keywords:	   purinergic	   receptor;	   missense	   mutation;	   single	   nucleotide	   polymorphism;	  
monocyte;	  dog	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INTRODUCTION	  
	  
Since	   the	   partial	   (31)	   and	   complete	   (33)	   sequencing	   of	   the	   canine	   genome	   there	   has	  
been	   considerable	   interest	   in	   the	   use	   of	   single	   nucleotide	   polymorphisms	   (SNPs)	   to	   help	  
explain	  the	  ancestry	  and	  evolutionary	  origins	  of	  the	  domestic	  dog	  (Canis	  lupus	  familiaris)	  (33,	  
53),	   as	   well	   as	   the	   phenotypic	   diversity	   between	   breeds	   (9).	   Moreover,	   as	   exemplified	   by	  
recent	  studies	  (30,	  46),	  there	  is	  continual	  interest	  in	  identifying	  SNPs	  associated	  with	  breed-­‐
specific	  disorders	  to	  determine	  the	  causes	  of	  such	  disorders	  in	  dogs	  and	  to	  help	  elucidate	  the	  
mechanisms	   involved	   in	   similar	   disorders	   within	   humans.	   One	   study	   that	   supports	   this	  
approach	   has	   been	   a	   genome-­‐wide	   association	   analysis,	   which	   identified	   a	   SNP	  within	   the	  
gene	   coding	   canine	   Cu/Zn	   SOD	   in	   breeds	   susceptible	   to	   degenerative	   myelopathy	   (3);	   a	  
disease	  similar	  to	  amyotrophic	  lateral	  sclerosis	  in	  humans,	  which	  is	  also	  associated	  with	  SNPs	  
in	   the	   gene	   coding	   human	   Cu/Zn	   SOD	   (43).	   This	   approach	   however	   is	   currently	   restricted.	  
First,	  presumably	  not	  all	  SNPs	  have	  been	  identified	  in	  the	  some	  350	  breeds	  that	  exist.	  Second,	  
as	  for	  humans	  the	  molecular	  and	  cellular	  effects	  of	  most	  canine	  SNPs	  identified	  to	  date	  are	  yet	  
to	  be	  fully	  elucidated.	  Thus,	  there	  is	  a	  need	  to	  identify	  novel	  SNPs	  within	  the	  dog,	  and	  to	  define	  
how	  these	  and	  existing	  SNPs	  influence	  canine	  biology.	  
The	  P2X7	  receptor	  is	  a	  trimeric	  ligand-­‐gated	  ion	  channel	  present	  on	  various	  cell	  types,	  
with	   high	   amounts	   present	   on	   the	   cell-­‐surface	   of	   monocytes	   (54).	   Upon	   activation	   by	   its	  
natural	   ligand	  ATP,	   the	  P2X7	  channel	   rapidly	  opens	  and	  dilates	   to	   form	  a	  pore	   to	  allow	   the	  
flux	  of	  organic	  cations	  and	  anions	  including	  fluorescent	  dyes	  (11).	  P2X7	  activation	  also	  results	  
in	  a	  variety	  of	  downstream	  events	  including	  the	  release	  of	  pro-­‐inflammatory	  mediators	  such	  
as	   IL-­‐1β,	   PGE2	  and	  CXC	  chemokine	   ligand	  16	   (4,	  38,	  40).	  Conversely	   in	   the	  absence	  of	  ATP,	  
P2X7	   may	   function	   as	   a	   scavenger	   receptor	   to	   facilitate	   the	   phagocytosis	   of	   bacteria	   and	  
apoptotic	   cells	   (23).	   As	   a	   result	   of	   these	   and	   other	   observations,	   P2X7	   is	   attracting	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considerable	  interest	  as	  a	  therapeutic	  target	  in	  various	  immune-­‐mediated	  disorders	  and	  pain	  
(36).	   P2X7	   activation	   is	   also	   important	   in	   physiological	   systems	   other	   than	   the	   immune	  
system	  such	  as	  bone	  homeostasis	  (52),	  and	  carbohydrate	  and	  lipid	  metabolism	  (2,	  6).	  
The	  human,	   canine,	   rhesus	  macaque,	   rat	   and	  murine	  P2X7	   subunits	  have	  been	   cloned	  
(10,	  12,	  41,	  42,	  51).	  Each	  of	  these	  mammalian	  P2X7	  subunits	  are	  595	  amino	  acids	  in	  length,	  
and	   comprise	   intracellular	   N-­‐	   and	   C-­‐termini,	   two	   trans-­‐membrane	   domains	   and	   a	   large	  
extracellular	  loop.	  The	  P2X7	  subunit	  is	  encoded	  by	  the	  P2RX7	  gene,	  which	  comprises	  13	  exons	  
and	  is	  highly	  polymorphic	  in	  humans,	  resulting	  in	  at	  least	  12	  loss-­‐of-­‐function	  and	  three	  gain-­‐
of-­‐function	  receptor	  variants	  (45).	  A	  loss-­‐of-­‐function	  SNP,	  P451L	  (rs48804829),	  has	  also	  been	  
described	  in	  mouse	  P2X7	  (1),	  but	  descriptions	  of	  SNPs	  in	  the	  P2RX7	  gene	  from	  other	  species	  
are	  limited.	  
Some	   40	   years	   ago,	   Parker	   and	   Snow	   demonstrated	   that	   extracellular	   ATP	   could	  
increase	  the	  membrane	  permeability	  of	  Beagle	  erythrocytes	  to	  cations	  (37).	  Nearly	  30	  years	  
later,	  our	  group	  using	  erythrocytes	  from	  English	  Springer	  Spaniels,	   identified	  that	  this	  effect	  
was	  mediated	  by	  P2X7	  (44),	  providing	  the	  first	  direct	  evidence	  that	  functional	  P2X7	  receptors	  
are	  present	  within	  dogs.	  Subsequently	  our	  group	  demonstrated	  that	  P2X7	  was	  also	  present	  on	  
monocytes,	  B	  cells	  and	  T	  cells	   from	  this	   (44,	  48),	  and	  more	  recently	   from	  other	  dog	  breeds	  
(25,	   47).	  However,	   the	  dog	  breeds	   in	  which	  P2X7	  has	  been	   studied	   are	   limited,	   and	   thus	   it	  
remains	   unknown	   if	   P2X7	   function	   varies	   between	   dogs	   or	   breeds.	   Two	   missense	   (non-­‐
synonymous)	   SNPs,	   F103L	   (rs23314713)	   and	   P452S	   (rs23315462),	   as	   well	   as	   one	  
synonymous	   SNP	   N131N	   (rs8660017)	   in	   the	   canine	   P2RX7	   gene	   have	   been	   reported	   in	  
databases	   of	   Ensembl	   (http://www.ensembl.org/index.html)	   or	   the	   National	   Centre	   for	  
Biotechnology	   Information	   (NCBI;	   http://www.ncbi.nlm.nih.gov/snp).	   However,	   the	  
functional	   effects	   of	   these	   SNPs	   remain	   unknown.	   The	   current	   study	   describes	   that	   the	  
relative	   P2X7	   function	   varies	   between	   dogs.	   Moreover,	   the	   current	   study	   confirms	   the	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presence	  of	   the	  F103L	  and	  P452S	  SNPs	   in	  canine	  P2X7,	  and	   identifies	   three	  other	  missense	  
SNPs,	  R270C,	  R365Q	  and	  L440F.	  Finally,	  using	  a	  recombinant	  P2X7,	  cloned	   from	  an	  English	  
Springer	  Spaniel,	  the	  current	  study	  demonstrates	  that	  the	  R270C	  SNP	  results	  in	  near	  complete	  
loss	  of	  function	  of	  canine	  P2X7.	  
	  
MATERIALS	  AND	  METHODS	  
	  
Materials.	  Ficoll-­‐Paque	  PLUS	  was	   from	  GE	  Healthcare	  Biosciences	  (Uppsala,	  Sweden).	  
YO-­‐PRO-­‐1	   iodide	   solution,	   ExoSAP-­‐IT,	   DMEM/F12	   medium,	   penicillin-­‐streptomycin,	   OPTI-­‐
MEM	  Reduced	  Serum	  Medium	  and	  Lipofectamine	  2000	  were	  from	  Invitrogen	  (Grand	  Island,	  
NJ).	   ATP,	   2’(3’)-­‐O-­‐(4-­‐benzoyl)benzoyl	   ATP	   (BzATP),	   adenosine	   5’-­‐O-­‐(3-­‐thio)triphosphate	  
(ATPγS),	   ADP,	   UTP,	  αβ-­‐methylene	   ATP	   (αβ-­‐meATP),	   Brilliant	   Blue	   G	   (BBG)	   and	   propidium	  
iodide	  were	  from	  Sigma	  Chemical	  Co	  (St	  Louis,	  MO).	  Allophycocyanin	  (APC)-­‐conjugated	  anti-­‐
canine	   CD14	   MAb	   (clone	   M5E2)	   was	   from	   BioLegend	   (San	   Diego,	   CA).	   SPHERO	   Rainbow	  
Fluorescent	  Particles	  were	   from	  Spherotech	   (Lake	  Forest,	   IL).	   Primers	   for	   sequencing	  were	  
obtained	   from	   GeneWorks	   (Hindmarsh,	   Australia).	   MangoTaq	   DNA	   polymerase	   was	   from	  
Bioline	   (London,	   UK).	   Primers	   for	   cloning	   were	   from	   Sigma	   Life	   Science	   (Castle	   Hill,	  
Australia).	   PfuUltra	  High-­‐Fidelity	  DNA	  polymerase	  was	   from	  Stratagene	   (La	   Jolla,	   CA).	  NheI	  
and	  NotI	  restriction	  enzymes	  were	  from	  Fermentas	  (Glen	  Burnie,	  MD).	  FBS	  was	  from	  Bovogen	  
Biologicals	  (East	  Keilor,	  Australia).	  Ethidium	  bromide	  was	  from	  Amresco	  (Solon,	  OH).	  Rabbit	  
anti-­‐mouse	  P2X7	  (extracellular	  epitope)	  polyclonal	  antibody	  (Ab)	  and	  blocking	  peptide,	  and	  
rabbit	   anti-­‐rat	   P2X7	   (C-­‐terminal	   epitope)	   Ab	   were	   from	   Alomone	   Labs	   (Jerusalem,	   Israel).	  
A438079,	  AZ10606120	  and	  AZ11645373	  were	  from	  Tocris	  Bioscience	  (Ellisville,	  MO).	  KN-­‐62	  
was	  from	  Alexis	  Biochemicals	  (Lausen,	  Switzerland).	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Samples.	   All	   canine	   samples	  were	   collected	   from	   privately	   owned	   dogs	   presented	   at	  
local	   veterinary	   clinics	   with	   informed	   consent	   of	   owners.	   All	   samples	   were	   collected	   in	  
accordance	   with	   institutional	   guidelines,	   and	   with	   approval	   from	   the	   Animal	   and	   Human	  
Ethics	  Committees	  of	  the	  University	  of	  Wollongong	  (Wollongong,	  Australia).	  
YO-­‐PRO-­‐12+	   uptake	   into	   canine	   monocytes.	   Peripheral	   blood	   was	   collected	   into	  
VACUETTE	   lithium	   heparin	   tubes	   (Greiner	   Bio-­‐One,	   Frickenheisen,	   Germany)	   from	   either	  
pedigree	   or	   cross	   breed	   dogs.	   Peripheral	   blood	   mononuclear	   cells	   (PBMCs)	   were	   isolated	  
from	  buffy	   coats	   using	   Ficoll-­‐Paque	   density	   centrifugation	   as	   described	   (48),	  washed	   twice	  
with	  phosphate-­‐buffered	  saline	  and	  once	  with	  NaCl	  medium	  (145	  mM	  NaCl,	  5	  mM	  KCl,	  5	  mM	  
glucose,	  0.1%	  BSA,	  10	  mM	  HEPES,	  pH	  7.4).	  PBMCs	  in	  NaCl	  medium	  (2	  x	  106	  cells/mL)	  were	  
pre-­‐incubated	  for	  5	  min	  at	  37oC	  before	  addition	  of	  1	  µM	  YO-­‐PRO-­‐12+	  followed	  15	  sec	  later	  by	  
the	  addition	  of	  1	  mM	  ATP.	  PBMCs	  were	  incubated	  in	  the	  absence	  or	  presence	  of	  ATP	  for	  5	  min,	  
before	   the	   addition	   of	   an	   equal	   volume	   of	   ice-­‐cold	   NaCl	   medium	   containing	   20	  mM	  MgCl2	  
(MgCl2	  medium)	  and	  centrifugation.	  PBMCs	  were	  washed	  once	  with	  NaCl	  medium	  and	   then	  
labelled	  with	  APC-­‐conjugated	  anti-­‐CD14	  mAb.	  Data	  were	  acquired	  using	  a	  BD	  (San	  Jose,	  CA)	  
LSR	   II	   flow	   cytometer,	   with	   a	   total	   of	   1	   x	   105	   events	   collected	   using	   emission	  windows	   of	  
515/20	  and	  660/20	  nm	  for	  YO-­‐PRO-­‐12+	  and	  APC,	  respectively.	  For	  each	  sample,	  the	  detector	  
for	   515/20	   nm	   was	   adjusted	   using	   SPHERO	   Rainbow	   Fluorescent	   Particles	   to	   a	   mean	  
fluorescence	  of	  10,000	  using	  BD	  FACSDiva	  software.	  The	  mean	  fluorescence	  intensity	  (MFI)	  of	  
YO-­‐PRO-­‐12+	   uptake	   was	   determined	   using	   FlowJo	   software	   (Tree	   Star,	   Ashland,	   OR).	   ATP-­‐
induced	   YO-­‐PRO-­‐12+	   uptake	   is	   presented	   as	   the	   mean	   difference	   (of	   duplicate	   samples)	  
between	  YO-­‐PRO-­‐12+	  uptake	  in	  the	  presence	  and	  absence	  of	  ATP.	  
P2RX7	  gene	  sequencing.	  DNA	  was	   isolated	   from	  canine	  peripheral	  blood	   (collected	  as	  
above)	  using	  the	  Wizard	  Genomic	  DNA	  Purification	  Kit	  (Promega,	  Madison,	  WI)	  according	  to	  
the	  manufacturer’s	  instructions	  and	  stored	  at	  -­‐80oC.	  Twelve	  primer	  pairs	  for	  exons	  1-­‐12	  and	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two	  overlapping	  primer	  pairs	  for	  exon	  13	  (Table	  1)	  were	  used	  to	  amplify	  individual	  exons	  of	  
the	   canine	  P2RX7	   gene	   by	   PCR.	   The	   PCR	  was	   conducted	   using	  MangoTaq	  DNA	   polymerase	  
with	  an	  initial	  denaturation	  at	  94oC	  for	  1	  min,	  followed	  by	  35	  cycles	  of	  denaturation	  at	  94oC	  
for	  30	  sec,	  annealing	  at	  58.6-­‐64.5oC	  (Table	  1)	  for	  30	  sec,	  and	  extension	  at	  72oC	  for	  1	  min.	  After	  
the	   cycling	   was	   completed,	   a	   final	   extension	   at	   72oC	   for	   5	   min	   was	   performed,	   and	   the	  
reactions	  returned	  to	  room	  temperature.	  The	  sequences	  of	  ExoSAP-­‐IT	  treated	  amplicons	  were	  
determined	   using	   the	   above	   primers	   with	   the	   ABI	   PRISM	   BigDye	   Terminator	   v3.1	   Cycle	  
Sequencing	  Kit	  (Applied	  Biosystems,	  Carlsbad,	  CA)	  and	  an	  Applied	  Biosystems	  3130xl	  Genetic	  
Analyzer.	   Resulting	   sequences	   were	   compared	   to	   the	   NCBI	   Reference	   Sequence	  
NM_001113456.1,	  which	  was	  defined	  as	  wild-­‐type	  canine	  P2X7.	  
Cloning	  of	  canine	  P2X7.	  cDNA	   from	  PBMCs	  of	   an	  English	  Springer	   Spaniel	  was	  kindly	  
provided	  by	  Peter	  Williamson	  and	  Rosanne	  Taylor	  (University	  of	  Sydney,	  Sydney,	  Australia)	  
and	  used	  as	  a	   template	  to	  clone	  canine	  P2X7	  using	  standard	  techniques.	  Canine	  P2X7	  cDNA	  
was	   amplified	   by	   PCR	   using	   PfuUltra	   High-­‐Fidelity	   DNA	   polymerase	   and	   the	   product	   was	  
cloned	  into	  the	  NheI/NotI	  sites	  of	  a	  pHumanP2X7-­‐AcGFP-­‐N1	  plasmid	  (49),	  from	  which	  human	  
P2X7-­‐AcGFP	   had	   been	   removed	   by	   double	   digestion	   with	  NheI/NotI.	   The	   sequence	   of	   the	  
resulting	  plasmid	   containing	   canine	  P2X7,	  pEnglish	  Springer	  Spaniel	  P2X7,	  was	  determined	  
using	   four	  overlapping	   forward	  and	   reverse	  primer	  pairs	   (5’	   to	  3’:	   CCGCCTGGTGTCCCATCG	  
and	   ATCTTCTTGATTCCATTCTCC;	   CCACCTCAGAGCCGTTCA	   and	   CAGCTGCATCTCCTCTG;	  
TGGCACCATTAAGTGGAT	   and	   GGTTCTGAGTCTTGTGAAAGGT;	   AGACAATTGTGGAGCCAA	   and	  
CTAGGTCCTGGGAGCCAAAG)	  with	   the	  ABI	  PRISM	  BigDye	  Terminator	   v3.1	  Cycle	   Sequencing	  
Kit	  and	  an	  Applied	  Biosystems	  3130xl	  Genetic	  Analyzer.	  Resulting	  sequences	  were	  compared	  
to	   the	   NCBI	   Reference	   Sequence	   NM_001113456.1,	   the	   earlier	   NCBI	   Reference	   Sequence	  
XM_534669.2	  (originally	  obtain	  from	  a	  Boxer	  as	  part	  of	  the	  canine	  genome	  project)	  (33)	  and	  
to	   the	   sequence	   of	   P2X7	   previously	   cloned	   from	   heart	   cDNA	   of	   a	   non-­‐disclosed	   dog	   breed	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(42).	  Plasmid	  DNA	  was	  isolated	  using	  the	  Wizard	  Plus	  SV	  Minipreps	  DNA	  Purification	  System	  
(Promega)	  according	  to	  the	  manufacturer’s	  instructions	  and	  stored	  at	  -­‐20oC.	  
Cell	   lines.	  Human	   embryonic	   kidney	   (HEK)-­‐293	   and	   murine	   microglial	   EOC13	   cells	  
were	  from	  the	  American	  Type	  Culture	  Collection	  (Rockville,	  MD).	  Madin-­‐Darby	  canine	  kidney	  
(MDCK)	  cells	  were	  from	  the	  European	  Collection	  of	  Cell	  Cultures	  (Porton	  Down,	  UK).	  HEK-­‐293	  
and	  MDCK	  cells	  were	  maintained	  in	  DMEM/F12	  medium	  supplemented	  with	  10%	  FBS,	  2	  mM	  
GlutaMAX,	   100	  U/mL	   penicillin	   and	   10	   μg/mL	   streptomycin	   (complete	   culture	  medium)	   at	  
37oC/5%	  CO2.	  Murine	  microglial	  EOC13	  cells	  were	  maintained	  as	  described	  (5).	  
Cell	  transfections.	  HEK-­‐293	  cells	  in	  complete	  culture	  medium	  (0.25-­‐0.5	  x	  106	  cells/mL)	  
were	   incubated	   overnight	   at	   37oC/5%	   CO2.	   Cells	   were	   then	   incubated	   in	   complete	   culture	  
medium	   containing	   4	   µg	   plasmid	   DNA	   and	   Lipofectamine	   2000	   (diluted	   in	   OPTI-­‐MEM	  
Reduced	  Serum	  Medium)	  for	  24	  h	  at	  37oC/5%	  CO2.	  The	  medium	  was	  then	  replaced	  and	  the	  
cells	  incubated	  for	  a	  further	  24	  h	  at	  37oC/5%	  CO2.	  
Fluorescent	  dye	  uptake	  into	  HEK-­‐293	  and	  MDCK	  cells.	  The	  uptake	  of	  ethidium+	  (or	  YO-­‐
PRO-­‐12+	  or	  propidium2+	  where	  indicated)	  into	  HEK-­‐293	  and	  MDCK	  cells	  in	  NaCl	  medium	  was	  
determined	  by	  flow	  cytometry	  as	  described	  (18).	  
Immunoblotting.	  Whole	  lysates	  of	  HEK-­‐293	  or	  EOC13	  cells	  were	  prepared	  as	  described	  
(13).	  Equal	  amounts	  of	  total	  protein	  were	  separated	  under	  reducing	  conditions	  using	  Any	  kD	  
Mini-­‐PROTEAN	   TGX	   Stain-­‐Free	   Gels	   and	   transferred	   to	   nitrocellulose	   membrane	   using	   a	  
Trans-­‐Blot	   Turbo	   Transfer	   System	   (all	   Bio-­‐Rad,	   Hercules,	   CA).	   Immunoblotting	   was	  
performed	   with	   an	   anti-­‐P2X7	   polyclonal	   Ab	   as	   described	   (13).	   To	   confirm	   equal	   protein	  
loading	  within	  stain-­‐free	  gels,	  total	  protein	  was	  measured	  using	  a	  Bio-­‐Rad	  Criterion	  Stain	  Free	  
Imager	  and	  Image	  Lab	  software.	  P2X7	  (75	  kDa)	  was	  detected	  using	  Amersham	  Hyperfilm	  ECL	  
(GE	  Healthcare,	  Little	  Chalfont,	  UK),	  and	  relative	  P2X7	  expression	  was	  measured	  using	  a	  Bio-­‐
Rad	  GS-­‐800	  Densitometer	  and	  ImageJ	  software	  (http://rsbweb.nih.gov/ij/).	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Site-­‐directed	   mutagenesis.	   Missense	   SNPs	   were	   introduced	   into	   pEnglish	   Springer	  
Spaniel	   P2X7	   using	   standard	   techniques	   and	   confirmed	   by	   sequencing	   (SUPAMAC,	   Sydney,	  
Australia)	  as	  described	  previously	  (49).	  
Immunocytochemistry.	  Immunolabeling	  of	  non-­‐permeabilized	  cells	  was	  performed	  with	  
an	  anti-­‐mouse	  P2X7	  polyclonal	  Ab	  as	  described	  (5).	  Cells	  were	  visualized	  using	  a	  TCS	  SP5	  II	  
confocal	   imagining	   system	   (Leica,	   Mannheim,	   Germany)	   (excitation	   at	   561	   nm;	   emission	  
collected	  at	  575-­‐630	  nm).	  
Electrophysiology.	  Whole	  cell	  patch-­‐clamp	  recordings	  of	  HEK-­‐293	  cells	  were	  performed	  
in	   low	   divalent	   solution	   (145	  mM	  NaCl,	   5	  mM	   KCl,	   0.2	  mM	   CaCl2,	   13	  mM	   glucose,	   10	  mM	  
HEPES,	   pH	   7.3,	   osm	   295-­‐310)	   and	   recorded	   using	   a	   HEKA	   (Lambrecht,	   Germany)	   EPC10	  
amplifier	  as	  described	  (7).	  
Data	   presentation	   and	   statistical	   analyses.	   Errors	   are	   expressed	   as	   SDs.	   Differences	  
between	   groups	   were	   compared	   using	   the	   One-­‐way	   ANOVA	   (using	   Tukey's	   multiple	  
comparison	   test).	   Measurements	   of	   ATP-­‐induced	   YO-­‐PRO-­‐12+	   uptake	   in	   canine	   monocytes	  
reflected	  a	  non-­‐Gaussian	  distribution	   (as	  determined	  by	   the	  D'Agostino	  &	  Pearson	  omnibus	  
normality	   test),	   thus	   differences	   in	   ATP-­‐induced	   YO-­‐PRO-­‐12+	   uptake	   between	   P2RX7	  
genotypes	   were	   compared	   using	   the	   Mann-­‐Whitney	   test	   or	   the	   Kruskal-­‐Wallis	   test	   (using	  
Dunn’s	   multiple	   comparison	   test).	   Statistical	   comparisons	   were	   made	   using	   Prism	   5	  




To	  determine	   if	   the	   relative	  P2X7	   function	  varied	  between	  dogs,	  blood	  was	  obtained	  
from	  dogs	   presented	   at	   local	   veterinary	   clinics	   and	   the	   ATP-­‐induced	   uptake	   of	   YO-­‐PRO-­‐12+	  
into	  CD14+	  monocytes	  determined	  by	  flow	  cytometry.	  Calibration	  beads	  were	  used	  to	  set	  the	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515/20	  nm	  detector	  of	  the	  flow	  cytometer	  for	  each	  sample.	  ATP	  induced	  YO-­‐PRO-­‐12+	  uptake	  
into	  monocytes	   from	  all	  52	  dogs	  studied,	  with	  an	  average	  MFI	  of	  152	  ±	  97	  (Fig.	  1).	  Relative	  
P2X7	  function	  varied	  between	  dogs.	  Within	  individual	  breeds	  where	  three	  or	  more	  dogs	  were	  
studied,	  relative	  P2X7	  function	  varied	  by	  at	  least	  two-­‐fold	  in	  both	  American	  Bull	  Terriers	  and	  
Staffordshire	   Bull	   Terriers,	   and	   up	   to	   13-­‐fold	   in	   Labrador	   Retrievers	   (Fig.	   1).	   Similarly,	  
relative	   P2X7	   varied	   amongst	   cross	   breed	   dogs	  with	   a	   13-­‐fold	   difference	   in	   P2X7	   function	  
between	  monocytes	  from	  a	  Border	  Collie	  and	  Australian	  Cattle	  Dog	  cross,	  and	  from	  a	  Golden	  
Retriever	  and	  Labrador	  Retriever	  cross,	  which	  had	  the	  highest	  (MFI	  of	  395)	  and	  lowest	  (MFI	  
of	  31)	  P2X7	  function,	  respectively	  (Fig.	  1).	  In	  contrast	  to	  canine	  monocytes,	  ATP	  was	  unable	  to	  
induce	  YO-­‐PRO-­‐12+	  uptake	  in	  MDCK	  cells	  over	  5	  min	  (MFI	  of	  0;	  Fig.	  1).	  
To	  determine	  if	  the	  variation	  in	  P2X7	  function	  between	  dogs	  was	  attributed	  to	  SNPs	  in	  
the	  P2RX7	  gene,	  the	  13	  exons	  of	  this	  gene	  from	  19	  dogs	  with	  either	  low	  or	  high	  P2X7	  function,	  
as	  well	  as	  from	  MDCK	  cells	  were	  sequenced.	  Sequences	  were	  compared	  to	  the	  NCBI	  Reference	  
Sequence	  NM_001113456.1,	  which	  was	   designated	   as	   the	  wild-­‐type	   canine	   P2X7	   sequence.	  
Sequencing	   confirmed	   the	   existence	   of	   the	   two	   previously	   reported	   missense	   SNPs,	  
rs23314713	   (ttc>ctc)	   in	   exon	   3	   and	   rs23315462	   (cct>tct)	   in	   exon	   13,	   which	   code	   for	   the	  
amino	  acid	   substitutions	  F103L	  and	  P452S,	   respectively	   (Fig.	   2A;	   Table	  2).	   Sequencing	   also	  
confirmed	   the	   existence	   of	   the	   previously	   reported	   synonymous	   SNP	   rs8660017	   (aat>aac;	  
N131N)	   in	   exon	   4	   of	   14	   dogs	   in	   either	   heterozygous	   (n=6)	   or	   homozygous	   dosage	   (n=8)	  
(results	  not	  shown).	  Finally,	  sequencing	  identified	  two	  novel	  missense	  SNPs,	  cgt>tgt	  in	  exon	  8	  
and	   cga>caa	   in	   exon	   11,	   which	   code	   for	   the	   amino	   acid	   substitutions	   R270C	   and	   R356Q,	  
respectively	  (Fig.	  2A;	  Table	  2).	  Complete	  sequences	  were	  obtained	  from	  all	  exons	  except	  for	  
exon	  13,	  for	  which	  the	  48	  base	  pairs	  coding	  the	  last	  16	  amino	  acid	  residues	  of	  the	  C-­‐terminus	  
of	  P2X7	  could	  not	  be	  resolved	  due	  to	  poor	  signal-­‐to-­‐noise	  ratio	  (results	  not	  shown).	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Next,	  exons	  3,	  8,	  11	  and	  13	  of	  the	  P2RX7	  gene	  were	  sequenced	  from	  the	  remaining	  dogs	  
with	   P2X7	   functional	   data,	   as	   well	   as	   from	   17	   other	   dogs	   for	   which	   genomic	   DNA	   was	  
available.	  The	  allele	  frequencies	  of	  F103L,	  R270C,	  R365Q	  and	  P452S	  were	  0.38,	  0.01,	  0.03	  and	  
0.39,	   respectively	   (Table	   2).	   Notably,	   the	   R270C	   SNP	  was	   only	   observed	   in	   a	   Cavalier	   King	  
Charles	   Spaniel	   and	  Cocker	   Spaniel	   cross	   and	   in	  MDCK	  cells,	  which	  were	  originally	  derived	  
from	  a	   Cocker	   Spaniel	   (16).	   In	   both	   instances	   the	  R270C	  SNP	  was	   present	   in	   heterozygous	  
dosage,	   and	   appeared	   to	   be	   linked	  with	   the	  P452S	   SNP	   (Table	   2).	   The	  R270C	   SNP	  was	  not	  
observed	   in	   a	   second	   Cocker	   Spaniel	   cross,	   from	   which	   no	   functional	   data	   was	   available	  
(Table	  2).	  The	  R365Q	  SNP	  was	  only	  observed	   in	   three	  Labrador	  Retrievers	  and	   in	  a	  Golden	  
Retriever	   and	   Labrador	   Retriever	   cross,	   and	   then	   only	   in	   heterozygous	   dosage	   in	   all	   four	  
cases;	  three	  other	  Labrador	  Retrievers	  were	  wild-­‐type	  at	  residue	  position	  365	  (Table	  2).	  
The	   relative	   P2X7	   function	   obtained	   above	   (Fig.	   1)	   was	   then	   compared	   to	   each	  
missense	  SNP	   individually.	  The	  P2X7	   function	  of	  dogs	  heterozygous	   for	   the	  F103L	  SNP	  was	  
similar	  to	  that	  of	  dogs	  wild-­‐type	  for	  F103,	  however	  the	  P2X7	  function	  of	  dogs	  homozygous	  for	  
this	   SNP	  was	   significantly	   lower	   compared	   to	  wild-­‐type	   animals	   (Fig.	   2B).	   Sample	  numbers	  
were	  limited	  for	  both	  the	  R270C	  and	  R365Q	  SNPs,	  and	  were	  only	  observed	  in	  heterozygous	  
dosage,	  but	  the	  mean	  P2X7	  function	  in	  dogs	  with	  either	  of	  these	  SNPs	  was	  about	  half	  that	  of	  
the	  mean	  P2X7	  function	  in	  dogs	  wild-­‐type	  for	  R270	  or	  R365	  (Fig.	  2B).	  In	  contrast,	  mean	  P2X7	  
function	  was	   similar	  between	  dogs	  wild-­‐type	   for	  P452,	  or	  heterozygous	  or	  homozygous	   for	  
the	  P452S	  SNP	  (Fig.	  2B).	  
Our	   group	   has	   previously	   characterized	   P2X7	   in	   erythrocytes	   and	   leukocytes	   from	  
English	  Springer	  Spaniels	  (44,	  48).	  Therefore,	  P2X7	  was	  cloned	  using	  cDNA	  from	  this	  breed	  to	  
generate	  a	  recombinant	  P2X7	  for	  site-­‐directed	  mutagenesis	  studies.	  The	  cloned	  receptor	  was	  
595	  amino	  acids	  in	  length	  (results	  not	  shown)	  and	  was	  wild-­‐type	  at	  amino	  acid	  positions	  103	  
(F103),	   270	   (R270)	   and	  365	   (R365)	   (Fig.	   3A)	   compared	   to	   the	   (wild-­‐type)	  NCBI	  Reference	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Sequence	  NM_001113456.1.	  In	  contrast,	  the	  cloned	  receptor	  differed	  at	  amino	  acid	  positions	  
440	  (L440F;	  ttg>ttt)	  and	  452	  (P452S;	  cct>tct)	  (Fig.	  3A).	  
To	  determine	  if	  the	  P2X7	  cloned	  from	  an	  English	  Springer	  Spaniel	  could	  be	  expressed	  
heterologously	  as	  a	  recombinant	  receptor	  in	  mammalian	  cells,	  whole	  lysates	  of	  HEK-­‐293	  cells	  
transfected	  with	  English	  Springer	  Spaniel	  P2X7	  plasmid	  DNA	  or	  mock-­‐transfected	  HEK-­‐293	  
cells	  were	   examined	   by	   immunoblotting	   using	   an	  Ab	   against	   an	   extracellular	   or	   C-­‐terminal	  
epitope	   of	   P2X7.	  Murine	   EOC13	   cells,	  which	   express	   endogenous	   P2X7	   (5),	  were	   used	   as	   a	  
positive	   control.	   Both	   antibodies	   detected	   a	   major	   band	   at	   75	   kDa,	   the	   predicted	   size	   of	  
glycosylated	   P2X7,	   in	   HEK-­‐293	   cells	   expressing	   English	   Springer	   Spaniel	   P2X7	   and	   EOC13	  
cells,	  but	  not	  mock-­‐transfected	  HEK-­‐293	  cells	  (Fig.	  3B).	  
Next,	   to	   determine	   if	   the	   P2X7	   cloned	   from	   an	   English	   Springer	   Spaniel	   could	   form	  
functional	   receptors	  when	   expressed	   heterologously	   in	  mammalian	   cells,	   a	   flow	   cytometric	  
assay	   was	   used	   to	   measure	   ATP-­‐induced	   fluorescent	   cation	   uptake	   into	   HEK-­‐293	   cells	  
expressing	  English	  Springer	   Spaniel	  P2X7	  or	  mock-­‐transfected	  HEK-­‐293	   cells.	  ATP	   failed	   to	  
induce	   ethidium+	   uptake	   into	   mock-­‐transfected	   HEK-­‐293	   cells	   (Fig.	   3C).	   In	   contrast,	   ATP	  
induced	   robust	   ethidium+	   uptake	   into	   HEK-­‐293	   cells	   expressing	   English	   Springer	   Spaniel	  
P2X7	   compared	   to	   corresponding	   cells	   incubated	   in	   the	   absence	   of	  ATP	   (Fig.	   3C).	   ATP	   also	  
induced	   robust	   uptake	   of	   two	   other	   fluorescent	   cations,	   YO-­‐PRO-­‐12+	   (375	   Da)	   and	  
propidium2+	   (415	   Da),	   as	   well	   ethidium+	   (314	   Da),	   into	   HEK-­‐293	   cells	   expressing	   English	  
Springer	  Spaniel	  P2X7	  (Fig.	  3D).	  
The	  recombinant	  English	  Springer	  Spaniel	  P2X7	  expressed	  heterologously	  in	  HEK-­‐293	  
cells	  was	  further	  characterized	  using	  flow	  cytometric	  measurements	  of	  ethidium+	  uptake.	  ATP	  
induced	  ethidium+	  uptake	  in	  a	  concentration-­‐dependent	  fashion	  with	  an	  EC50	  value	  of	  253	  µM	  
(Fig.	  3E).	  Moreover,	  BzATP	  and	  ATPγS,	  agonists	  of	  endogenous	  and	  recombinant	  human	  P2X7	  
(15,	  19),	  induced	  ethidium+	  uptake	  in	  a	  concentration-­‐dependent	  fashion	  and	  with	  EC50	  values	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of	  13	  and	  438	  µM,	  respectively	  (Fig.	  3E).	  Maximum	  ethidium+	  uptake	  was	  observed	  with	  50	  
µM	  BzATP,	  while	  ATP	  and	  ATPγS	  represented	  partial	  agonists.	  In	  contrast,	  ADP,	  UTP	  and	  αβ-­‐
meATP	  (each	  at	  1	  mM)	  failed	  to	  induce	  ethidium+	  uptake	  (Fig.	  3E).	  
The	  efficacy	  of	   five	  well-­‐known	  human	  and	  rodent	  P2X7	  antagonists	  was	   then	  tested	  
against	   the	   recombinant	   English	   Springer	   Spaniel	   P2X7.	   A438079	   (35),	   AZ10606120	   (34),	  
AZ11645373	   (50),	   BBG	   (28)	   and	   KN-­‐62	   (20)	   impaired	   ATP-­‐induced	   ethidium+	   uptake	   in	   a	  
concentration-­‐dependent	  fashion	  with	  IC50	  values	  of	  195	  nM,	  11	  nM,	  9	  nM,	  1000	  nM	  and	  16	  
nM,	   respectively	   (Fig.	   3F).	  Moreover,	   all	   five	   antagonists	   completely	   impaired	   ATP-­‐induced	  
ethidium+	   uptake	   with	   maximal	   inhibition	   observed	   at	   concentrations	   of	   0.1	   µM	   for	  
AZ10606120	  and	  AZ11645373,	  1	  µM	  for	  KN-­‐62,	  and	  10	  µM	  for	  A438079	  and	  BBG	  (Fig.	  3F).	  
To	   determine	   if	   any	   of	   the	  missense	   SNPs	   identified	   above	   (F103L,	   R270C,	   R365Q,	  
L440F	   and	   P452S)	   effect	   P2X7	   function,	   the	   cloned	   English	   Springer	   Spaniel	   P2X7	   was	  
mutated	   as	   follows.	   First,	   the	   plasmid	   containing	   the	   cloned	  English	   Springer	   Spaniel	   P2X7	  
(which	  contained	  both	  the	  440F	  and	  452S	  SNPs;	  now	  termed	  440F/452S	  mutant	  P2X7)	  was	  
changed	   to	   wild-­‐type	   at	   position	   440	   (termed	   452S	   mutant	   P2X7)	   by	   mutating	   the	  
phenylalanine	  residue	  to	  leucine.	  Next,	  the	  plasmid	  containing	  only	  the	  452S	  SNP	  was	  either	  
changed	   to	   wild-­‐type	   P2X7	   (termed	   wild-­‐type	   P2X7)	   by	   mutating	   the	   serine	   residue	   at	  
position	  452	  to	  proline	  or	  changed	  to	  a	  double	  mutant	  (termed	  270C/452S	  mutant	  P2X7)	  by	  
mutating	  the	  arginine	  residue	  at	  position	  270	  to	  cysteine.	  Finally,	  the	  wild-­‐type	  P2X7	  plasmid	  
was	  mutated	  to	  contain	  either	  the	  103L	  or	  365Q	  SNP	  (termed	  103L	  and	  365Q	  mutant	  P2X7,	  
respectively).	  
Using	   the	   above	   plasmids,	   the	   effect	   of	   each	   SNP	   on	   P2X7	   function	   assessed	   by	  
measurements	  of	  ATP-­‐induced	  ethidium+	  uptake	  into	  transfected	  HEK-­‐293	  cells.	  ATP-­‐induced	  
ethidium+	   uptake	   was	   24%	   less	   in	   cells	   expressing	   452S	   mutant	   P2X7	   compared	   to	   cells	  
expressing	   440F/452S	   mutant	   P2X7	   (Fig.	   4A).	   ATP-­‐induced	   ethidium+	   uptake	   into	   cells	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expressing	  452S	  mutant	  P2X7	  was	  similar	  to	  that	  of	  cells	  expressing	  wild-­‐type	  P2X7	  (Fig.	  4B).	  
In	   contrast,	   ATP-­‐induced	   ethidium+	   uptake	   was	   almost	   completely	   abolished	   in	   cells	  
expressing	  270C/452S	  mutant	  P2X7	   compared	   to	   cells	   expressing	   either	  wild-­‐type	  or	  452S	  
mutant	  P2X7	  (Fig.	  4B).	  Finally,	  ATP-­‐induced	  ethidium+	  uptake	  was	  46%	  and	  37%	  less	  in	  cells	  
expressing	  either	  103L	  or	  365Q	  mutant	  P2X7,	  respectively	  compared	  to	  cells	  expressing	  wild-­‐
type	  P2X7	  (Fig.	  4C).	  
To	  determine	  if	   the	  differences	   in	  ATP-­‐induced	  ethidium+	  uptake	  in	  transfected	  HEK-­‐
293	   cells	   related	   to	   total	   P2X7	   expression,	  whole	   lysates	   of	  HEK-­‐293	   cells	   transfected	  with	  
DNA	  from	  wild-­‐type	  or	  each	  mutant	  P2X7	  plasmid	  were	  examined	  by	  immunoblotting	  using	  
the	  Ab	  against	  the	  extracellular	  epitope	  of	  P2X7	  and	  the	  amount	  of	  P2X7	  quantified.	  As	  above	  
(Fig.	  3B),	  a	  major	  band	  at	  75	  kDa	  was	  detected	   in	   lysates	  of	  HEK-­‐293	  cells	  expressing	  wild-­‐
type	  or	  mutant	  P2X7	   (Fig.	  4D-­‐F).	  The	  amount	  of	  P2X7	  was	  29%	   less	   in	   cells	  expressing	   the	  
452S	  mutant	  compared	  to	  cells	  expressing	  440F/452S	  mutant	  P2X7	  (Fig.	  4D).	  The	  amount	  of	  
P2X7	   was	   22%	   and	   30%	   less	   in	   cells	   expressing	   either	   452S	   or	   270C/452S	   mutant	   P2X7	  
respectively	  compared	  to	  cells	  expressing	  wild-­‐type	  P2X7	  (Fig.	  4E).	  The	  amount	  of	  P2X7	  was	  
48%	   and	   32%	   less	   in	   cells	   expressing	   either	   103L	   or	   365Q	   mutant	   P2X7	   respectively	  
compared	  to	  cells	  expressing	  wild-­‐type	  P2X7	  (Fig.	  4F).	  
The	  above	  data	  indicates	  that	  the	  R270C	  SNP	  has	  a	  major	  functional	  impact	  on	  canine	  
P2X7.	  Therefore,	  this	  SNP	  was	  characterised	  further	  in	  HEK-­‐293	  cells	  expressing	  either	  wild-­‐
type,	  452S	  or	  270C/452S	  mutant	  P2X7.	  First,	  patch-­‐clamp	  measurements	  revealed	  that	  ATP	  
induced	  robust	  inward	  currents	  in	  HEK-­‐293	  cells	  expressing	  wild-­‐type	  or	  452S	  mutant	  P2X7,	  
with	  mean	  current	  densities	  of	  49	   (19)	  pA/pF	  (n=6)	  and	  39	  (24)	  pA/pF	  (n=7),	   respectively	  
and	  which	  were	  not	  significantly	  different	  (P>0.05)	  (Fig.	  5A).	  In	  contrast,	  ATP-­‐induced	  inward	  
currents	   in	   HEK-­‐293	   cells	   expressing	   270C/452S	   mutant	   P2X7	   were	   significantly	   smaller	  
(mean	  current	  density	  of	  3	  (1)	  pA/pF,	  n=5)	  than	  those	  observed	  in	  HEK-­‐293	  cells	  expressing	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wild-­‐type	   or	   452S	   mutant	   P2X7	   (P<0.01	   and	   P<0.05,	   respectively)	   (Fig.	   5A).	   In	   addition,	  
multiple	   applications	   of	   ATP	   saw	   wild-­‐type	   or	   452S	   mutant	   P2X7	   display	   facilitation	   of	  
responses	  over	  5	  min,	  whereas	  270C/452S	  mutant	  P2X7	  responses	  did	  not	  display	  facilitation	  
and	   remained	   small	   (Fig.	   5B).	   Second,	   immunolabeling	   with	   an	   Ab	   specific	   for	   the	  
extracellular	   loop	  of	  P2X7	  and	  confocal	  microscopy	  demonstrated	  cell-­‐surface	  expression	  of	  
P2X7	   on	  HEK-­‐293	   cells	   expressing	  wild-­‐type,	   452S	   or	   270C/452S	  mutant	   P2X7	   (Fig.	   6).	   In	  
contrast,	  immunoreactivity	  of	  mock-­‐transfected	  HEK-­‐293	  cells	  with	  anti-­‐P2X7	  Ab,	  or	  HEK-­‐293	  
cells	   expressing	  wild-­‐type	   or	  mutant	   P2X7	   incubated	   in	   the	   presence	   of	   anti-­‐P2X7	  Ab	  with	  




The	  current	  study	  aimed	  to	  assess	  the	  functional	  impact	  of	  P2X7	  variation	  in	  a	  random	  
sample	  of	   the	  canine	  population.	  Others	  and	  us	  have	  previously	  shown	  that	  monocyte	  P2X7	  
function	   correlates	   with	   P2RX7	   genotype	   in	   humans	   (14,	   24,	   49).	   Thus,	   the	   variable	   P2X7	  
function	   between	   dog	   breeds	   and	  within	   individual	   breeds	  may	   in	   part	   be	   caused	   by	   SNPs	  
within	  the	  canine	  P2RX7	  gene.	  Of	  the	  P2RX7	  SNPs	  identified	  F103L,	  R270C	  and	  R365Q,	  but	  not	  
P452S,	  corresponded	  to	  decreased	  P2X7	  function	  in	  canine	  monocytes.	  However	  these	  SNPs	  
could	  not	  explain	  the	  majority	  of	  differences	   in	  P2X7	  function	  between	  dogs,	   indicating	  that	  
other	  factors	  contribute	  to	  this	  variability.	  Such	  factors	  may	  include	  SNPs	  in	  the	  last	  48	  base	  
pairs	   of	   exon	   13	   and	   in	   the	   promoter	   and	   intronic	   regions	   of	   the	   P2RX7	   gene,	   differential	  
expression	   of	   P2X7	   splice	   variants,	   or	   differences	   in	   the	   health	   status	   of	   dogs	   upon	  
presentation	  at	  local	  veterinary	  clinics.	  
Of	  the	  SNPs	  identified	  in	  our	  dog	  population	  and	  our	  cloned	  English	  Springer	  Spaniel	  
P2X7	  (Fig.	  7),	  the	  R270C	  SNP	  was	  concluded	  to	  be	  a	  loss-­‐of-­‐function	  SNP	  impairing	  both	  P2X7	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channel	   activity	   and	   pore	   formation.	   To	   the	   best	   of	   our	   knowledge	   this	   SNP	   has	   not	   been	  
previously	  reported,	  but	  a	  R270H	  SNP	  (rs7958311)	  has	  been	   identified	   in	  human	  P2X7	  and	  
confers	  a	  partial	  loss	  of	  function	  (49).	  Thus,	  this	  latter	  result	  indirectly	  supports	  the	  concept	  
that	   R270C,	   which	   exchanges	   a	   positively	   charged	   arginine	   residue	   for	   a	   polar,	   uncharged	  
cysteine	  residue,	  is	  a	  loss-­‐of-­‐function	  SNP	  in	  canine	  P2X7.	  Structural	  modeling	  of	  human	  P2X7	  
places	   the	  R270	  residue	  and	   the	  neighboring	  R276	  residue,	  which	   is	   the	  site	   for	   the	  R276H	  
loss-­‐of-­‐function	  SNP	  (49),	   in	   the	  β12	  strand	  of	   the	   lower	  body	  of	   the	  extracellular	   loop	  and	  
away	  from	  the	  ATP-­‐binding	  site	  (27).	  As	  such,	  Jiang	  and	  colleagues	  proposed	  that	  the	  R276H	  
SNP	  maybe	   involved	   in	   conformational	   changes	   associated	  with	   channel	   gating	   or	   receptor	  
activation/deactivation	  (27).	  Thus	  by	  extension,	  it	  is	  possible	  that	  the	  R270C	  SNP	  may	  also	  act	  
in	  a	  similar	  way	  to	  negatively	  effect	  P2X7	  function.	  Alternatively,	  since	  this	  SNP	  introduces	  a	  
cysteine	  adjacent	   to	   the	  existing	   cysteine	  at	  position	  269,	   it	   is	  possible	   that	   the	  R270C	  SNP	  
disrupts	   the	   potential	   disulfide	   bond	   between	   C260	   and	   C269	   (29)	   to	   reduce	   receptor	  
function	   by	   altering	   the	   structure	   of	   the	   P2X7	   subunit.	   Disulfide	   bonds	   of	   the	   extracellular	  
loop	  of	  P2X7	  are	   also	   essential	   for	   its	   trafficking	   to	   the	  plasma	  membrane	   (29),	   however	   it	  
appears	  unlikely	  that	  R270C	  SNP	  impairs	  trafficking	  of	  the	  canine	  P2X7	  to	  the	  cell-­‐surface	  as	  
immunocytochemistry	  showed	  the	  presence	  of	  cell-­‐surface	  P2X7	  on	  HEK-­‐293	  cells	  expressing	  
P2X7	  containing	  this	  SNP.	  
The	  missense	  SNPs,	  F103L	  and	  R365Q,	  in	  canine	  P2X7	  may	  be	  partial	  loss-­‐of-­‐function	  
SNPs.	   However	   the	   current	   body	   of	   evidence	   is	   limited	   as	   total	   P2X7	   expression	   was	   also	  
reduced	  by	  a	  similar	  amount	  in	  HEK-­‐293	  cells	  transfected	  with	  either	  mutant	  P2X7	  compared	  
to	   cells	   transfected	  with	   wild-­‐type	   P2X7.	   Thus,	   whether	   the	   lower	   P2X7	   function	   of	   either	  
mutant	  receptor	  is	  due	  to	  reduced	  P2X7	  protein	  synthesis	  or	  half-­‐life,	  or	  plasmid	  transfection	  
efficiency	  remains	  to	  be	  determined.	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In	  contrast	  to	  the	  other	  missense	  SNPs	  in	  canine	  P2X7,	  it	  is	  reasonable	  to	  conclude	  that	  
the	  P452S	  SNP	  does	  not	  alter	  P2X7	   function.	   It	   is	  noteworthy	   that	   the	  P452S	  SNP	   in	  canine	  
P2X7	  is	  located	  at	  the	  equivalent	  position	  to	  that	  of	  the	  partial	  loss-­‐of-­‐function	  P451L	  SNP	  in	  
murine	  P2X7,	  which	  is	  present	  in	  some	  but	  not	  all	  mouse	  strains	  (1).	  This	  difference	  in	  effect	  
between	  canine	  P452S	  and	  murine	  P451L	  on	  P2X7	  function	  may	  relate	  to	  differences	  between	  
the	  hydrophilic	  and	  larger	  hydrophobic	  side	  chain	  of	  serine	  and	  leucine,	  respectively.	  
The	   current	   study	   involved	   the	   cloning	   of	   canine	   P2X7	   from	   an	   English	   Springer	  
Spaniel	  for	  use	  in	  site-­‐directed	  mutagenesis	  studies	  to	  examine	  the	  effects	  of	  identified	  SNPs	  
on	   P2X7	   function.	   This	   breed	   was	   originally	   chosen	   following	   our	   original	   studies	   of	  
endogenous	  P2X7	  in	  this	  breed	  (44,	  48).	  Compared	  to	  wild-­‐type	  canine	  P2X7	  (NCBI	  Reference	  
Sequence	  NM_001113456.1),	  the	  cloned	  English	  Springer	  Spaniel	  P2X7	  differed	  by	  two	  amino	  
acid	   residues,	  L440F	  and	  P452S.	  The	  P452S	  SNP	  had	  an	  allele	   frequency	  of	  0.39	   in	  our	  dog	  
population.	   In	   contrast,	   the	   L440F	   SNP	   has	   not	   been	   previously	   reported	   and	   was	   not	  
observed	  in	  any	  other	  dog	  for	  which	  exon	  13	  was	  sequenced	  (results	  not	  shown).	  Whether	  this	  
variant	   represents	   a	   SNP	   in	   English	   Springer	   Spaniels	   or	  was	   introduced	   as	   a	   result	   of	   the	  
cloning	  process	  remains	  unknown.	  
Pharmacological	   characterization	   of	   the	   recombinant	   English	   Springer	   Spaniel	   P2X7	  
demonstrated	   that	   this	   receptor	   displays	   rank	   orders	   of	   agonist	   and	   antagonist	   potencies	  
similar	   to	   that	   of	   endogenous	   and	   recombinant	  human	  P2X7	   (15,	   19,	   39).	  Of	  note,	   the	  EC50	  
values	   for	   BzATP	   and	   ATP	   were	   similar	   to	   that	   described	   for	   endogenous	   P2X7	   in	  
erythrocytes	  from	  English	  Springer	  Spaniels	  (48).	  Moreover,	  study	  of	  both	  endogenous	  P2X7	  
(48)	   and	   the	   recombinant	   English	   Springer	   Spaniel	   P2X7	   revealed	   that	   ATP	   was	   a	   partial	  
agonist	  compared	  to	  BzATP.	  These	  results	  contrast	  findings	  with	  the	  previously	  cloned	  canine	  
P2X7	   of	   Roman	   and	   colleagues,	   which	   demonstrated	   that	   BzATP	   was	   a	   partial	   agonist	   of	  
canine	   P2X7	   compared	   to	   ATP	   (42).	   The	   reason	   for	   this	   difference	   between	   these	   studies	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remains	  unknown	  but	  one	  possible	  explanation	  is	  the	  amino	  acid	  at	  position	  103	  alters	  BzATP	  
sensitivity.	  
In	  conclusion,	   the	  current	  study	   identified	  a	  missense	  SNP,	  R270C,	  which	   leads	   to	  a	  
loss	   of	   function	   of	   canine	  P2X7.	   It	  will	   be	   of	   importance	   in	   future	   studies	   to	   determine	   the	  
frequency	  of	  this	  SNP	  in	  Cocker	  Spaniels	  and	  other	  breeds,	  and	  to	  determine	  whether	  this	  SNP	  
disrupts	   P2X7-­‐mediated	   physiological	   processes,	   such	   as	   ATP-­‐induced	   IL-­‐1β	   release.	  
Moreover,	  since	  SNPs	  in	  the	  human	  P2RX7	  gene	  are	  associated	  with	  various	  diseases	  (17,	  21,	  
22,	   32),	   and	   that	   a	   three	   base-­‐pair	   deletion	   in	   the	   gene	   coding	   the	   P2Y12	   receptor	   is	  
associated	  with	  post-­‐operative	  hemorrhage	  in	  a	  Greater	  Swiss	  Mountain	  dog	  (8),	  it	  will	  be	  of	  
interest	   to	   determine	  whether	   the	  R270C	   SNP	  or	   other	   SNPs	   in	   the	   canine	  P2RX7	   gene	   are	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Fig.	   1.	   Relative	   monocyte	   P2X7	   function	   varies	   between	   dogs.	   PBMCs	   (from	   52	   dogs	   as	  
indicated)	  or	  MDCK	  cells	  in	  NaCl	  medium	  containing	  1	  µM	  YO-­‐PRO-­‐12+	  were	  incubated	  in	  the	  
absence	  or	  presence	  of	  1	  mM	  ATP	  for	  5	  min	  at	  37oC.	  Incubations	  were	  stopped	  by	  addition	  of	  
MgCl2	  medium	   and	   centrifugation,	   and	   YO-­‐PRO-­‐12+	   uptake	   into	   CD14+	  monocytes	   or	  MDCK	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cells	   determined	   by	   flow	   cytometry.	   ATP-­‐induced	   YO-­‐PRO-­‐12+	   uptake	   was	   defined	   as	   the	  
mean	  difference	  (from	  duplicate	  samples)	  in	  mean	  fluorescent	  intensity	  in	  the	  presence	  and	  
absence	  of	  ATP	  for	  each	  individual.	  Symbols	  represent	  individual	  dogs;	  bars	  represent	  group	  
means;	  broken	  line	  represents	  mean	  of	  all	  samples.	  
	  
Fig.	  2.	  The	  F103L,	  R270C	  and	  R365Q	  SNPs	  correspond	  to	  decreased	  monocyte	  P2X7	  function.	  
A:	  Sequence	  analysis	  of	  the	  canine	  P2RX7	  gene	  identified	  four	  missense	  SNPs	  as	  indicated.	  The	  
L440F	  SNP	  identified	  in	  the	  cloned	  English	  Springer	  Spaniel	  P2X7	  (but	  absent	  in	  all	  other	  dogs	  
sequenced)	  is	  also	  shown.	  Boxes	  represent	  P2RX7	  exons	  (not	  all	  13	  exons	  are	  represented).	  B:	  
For	  each	  dog,	  the	  P2RX7	  genotype	  (as	  indicated)	  was	  compared	  to	  the	  relative	  monocyte	  P2X7	  
function	   (obtained	   in	   Fig.	   1).	   *P<0.05	   to	   corresponding	   wild-­‐type.	   Symbols	   represent	  
individual	  dogs;	  bars	  represent	  group	  means.	  
	  
Fig.	  3.	  Characterization	  of	  P2X7	  cloned	  from	  an	  English	  Springer	  Spaniel.	  A:	  Sequence	  analysis	  
of	  the	  P2X7	  cloned	  from	  an	  English	  Springer	  Spaniel	  revealed	  two	  missense	  SNPs,	  440F	  and	  
452S,	  but	  was	  wild-­‐type	   for	  F103,	  R270	  and	  R365	  as	   shown.	  Boxes	   represent	  P2RX7	   exons	  
(not	  all	  13	  exons	  are	  represented).	  B:	  Whole	  lysates	  of	  EOC13	  cells,	  HEK-­‐293	  cells	  transfected	  
with	   English	   Springer	   Spaniel	   P2X7	   plasmid	   DNA	   or	  mock-­‐transfected	   HEK-­‐293	   cells	   were	  
examined	  by	  immunoblotting	  using	  an	  Ab	  against	  either	  the	  (left	  panel)	  extracellular	  epitope	  
or	   (right	   panel)	   C-­‐terminal	   epitope	   of	   P2X7.	   C-­‐F:	   HEK-­‐293	   cells	   transfected	   with	   English	  
Springer	   Spaniel	   P2X7	  plasmid	  DNA	  or	  mock-­‐transfected	  HEK-­‐293	   cells	  were	   suspended	   in	  
NaCl	  medium	  containing	  (C-­‐F)	  25	  µM	  ethidium+,	  (D)	  1	  µM	  YO-­‐PRO-­‐12+	  or	  25	  µM	  propidium2+	  
at	  37oC.	  (C,	  D)	  Cells	  were	  incubated	  in	  the	  absence	  (basal)	  or	  presence	  of	  1	  mM	  ATP	  for	  5	  min.	  
E:	  Cells	  were	  incubated	  in	  the	  absence	  or	  presence	  of	  ATP,	  BzATP	  or	  ATPγS	  as	  indicated,	  or	  1	  
mM	  ADP,	  UTP	  or	  αβ-­‐meATP	  for	  5	  min.	  F:	  Cells	  were	  preincubated	  in	  the	  absence	  or	  presence	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of	   A438079,	   AZ10606120,	   AZ11645373,	   BBG	   or	   KN-­‐62	   as	   indicated	   for	   15	   min,	   before	  
addition	  of	  ethidium+,	  and	  incubation	  in	  the	  absence	  or	  presence	  of	  250	  µM	  ATP	  (equivalent	  
to	  the	  EC50	   for	  ATP)	   for	  5	  min.	  C-­‐F:	   Incubations	  were	  stopped	  by	  addition	  of	  MgCl2	  medium	  
and	  centrifugation,	  and	  cation	  dye	  uptake	  determined	  by	  flow	  cytometry.	  Cation	  dye	  uptake	  is	  
expressed	  as	   (C,	  D)	  mean	   fluorescent	   intensity,	   (E)	  percent	  of	  maximum	  response	   to	  50	  µM	  
BzATP	   or	   (F)	   percent	   of	   maximum	   response	   to	   250	   µM	   ATP	   in	   the	   absence	   of	   antagonist.	  
Results	  are	  mean	  (SD),	  n=3;	  **P<0.01	  to	  corresponding	  basal.	  
	  
Fig.	   4.	   The	   R270C	   SNP	   results	   in	   loss	   of	   function	   of	   canine	   P2X7.	   A-­‐C:	   HEK-­‐293	   cells,	  
transfected	  with	  wild-­‐type	  or	  mutant	  canine	  P2X7	  plasmid	  DNA	  (as	  indicated),	  suspended	  in	  
NaCl	  medium	  containing	  25	  µM	  ethidium+	  were	  incubated	  in	  the	  absence	  (basal)	  or	  presence	  
of	  1	  mM	  ATP	  for	  5	  min	  at	  37oC.	  Incubations	  were	  stopped	  by	  addition	  of	  MgCl2	  medium	  and	  
centrifugation.	  Ethidium+	  uptake	  was	  determined	  by	  flow	  cytometry	  and	  expressed	  as	  mean	  
fluorescent	   intensity.	   Results	   are	   mean	   (SD),	   n=3-­‐4;	   **P<0.01	   to	   corresponding	   basal,	  
**P<0.01	  to	  (A)	  440F/452S	  or	  (B,	  C)	  corresponding	  wild-­‐type.	  D-­‐F:	  Whole	  lysates	  of	  HEK-­‐293	  
cells	   transfected	   with	   wild-­‐type	   or	   mutant	   canine	   P2X7	   plasmid	   DNA	   (as	   indicated)	   were	  
examined	  by	  immunoblotting	  using	  an	  Ab	  against	  the	  extracellular	  epitope	  of	  P2X7.	  
	  
Fig.	   5.	   The	   R270C	   SNP	   results	   in	   loss	   of	   canine	   P2X7	   channel	   activity.	   HEK-­‐293	   cells	  were	  
transfected	   with	   wild-­‐type	   (left	   panel),	   452S	   mutant	   (middle	   panel)	   or	   270C/452S	   (right	  
panel)	  canine	  P2X7	  plasmid	  DNA.	  Cells	  were	  clamped	  at	  -­‐60	  mV	  at	  room	  temperature,	  1	  mM	  
ATP	   in	   low	   divalent	   solution	  was	   applied	   using	   a	   fast-­‐flow	   delivery	   system	   and	  whole	   cell	  
currents	   were	   recorded.	   (A)	   Inward	   current	   to	   first	   exposure	   to	   ATP	   and	   (B)	   repeated	  
exposures	   to	   ATP	   every	   60	   sec.	   Black	   bars	   indicate	   ATP	   exposure	   (5	   sec).	   Traces	   are	  
representative	  of	  five	  to	  seven	  cells.	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Fig.	  6.	  Canine	  P2X7	  containing	  the	  R270C	  SNP	  is	  expressed	  on	  the	  cell-­‐surface	  of	  transfected	  
HEK-­‐293	   cells.	   HEK-­‐293	   cells	   transfected	   with	   wild-­‐type	   (top	   panel),	   452S	  mutant	   (middle	  
panel)	   or	   270C/452S	  mutant	   (bottom	  panel)	   canine	   P2X7	   plasmid	   DNA	  were	   examined	   by	  
immunolabeling	   with	   an	   Ab	   specific	   for	   the	   extracellular	   loop	   of	   P2X7	   and	   confocal	  
microscopy.	  
	  
Fig.	  7.	  SNPs	  of	  canine	  P2X7.	  P2X7	  protein	  alignment	  of	  sequences	  from	  five	  species	  illustrating	  
the	   relative	   position	   of	   (bold)	   five	   missense	   SNPs	   and	   one	   synonymous	   SNP	   identified	   in	  
canine	  P2X7	  (canine	  P2X7	  numbering).	  (Highlighted	  grey)	  Missense	  SNPs	  identified	  in	  human	  
(R270H)	   and	  mouse	   (P451L,	  mouse	   P2X7	   numbering)	   P2X7	   in	   equivalent	   positions	   to	   270	  
and	  452	  in	  canine	  P2X7	  are	  also	  shown.	  The	  sequences	  correspond	  to	  the	  following	  accession	  
numbers	   or	   references:	   NM_001113456	   (canine,	   NCBI,	   National	   Center	   for	   Biotechnology	  
Information);	  XM_534669	  (canine,	  Boxer);	  Ref.	  (42)	  (canine,	  GSK,	  GlaxoSmithKline);	  and	  the	  
current	   study	   (canine,	   EES,	   English	   Springer	   Spaniel);	   Y09561	   (human);	   Ref.	   (10)	   (rhesus	  
macaque);	  X95882	  (rat);	  AJ009823	  (mouse).	  
Table 1. Primers used to amplify and sequence the canine P2RX7 gene 
Exon Forward Primer (5’-3’) Reverse primer (5’-3’) Size (bp)* Temp (oC)† 
1 AGGATTGAACCCTCCTCGTT TCAAGATGTGCACCAGAAGC 263 58.7 
2 AAGTAGCCTGCCCAGAGTCA TTTTGAGCTGCTGGATCTGA 486 64.1 
3 AGTCCAAGTTGCTCCCAGAC GAGGACAGAAGAGGGAAAAGA 349 63.1 
4 TCCTGTTGTAGCAGGTGCAG GCTGAGAGCCAGAGGCTAAA 423 64.1 
5 AAAAAGCCAACAGCATCCAC CTCTTCCTCCCCTGCTCTTT 741 60.0 
6 GGGCCTCAGGAAGAGAGAAG CCCACAGAAACTGCATCAGA 346 64.5 
7 CATGGAACCCAGCTACCAAC GCACTGTGCCGGGATATACT 353 64.1 
8 TTTAATCTGCGTTCCCCTCT AAGCCTTTTGCATTCATCTTG 368 63.1 
9 TGAAATACCAGCATGTTCAC GGACATTTCTTCCCCCTCTT 263 58.7 
10 GCTGACAATTACATGGTAGAGCA CTAAAGTGTAGGAAAGAGAA 170 62.2 
11 CTCACTAACTCGCACTGAT TGATTTTGGCCTTATTTTTGC 262 62.2 
12 GAATAACACTTGCCTTTAGATATGTTC TGGGTTACATGTACTTAATGTGTTAAA 300 60.0 
13‡ GAACCTTAGGGGTGGTCACT CAAGCTCAGGTGCAAACAAA 600 64.1 
13‡ TTTCAGAGACCCTCAATGGAA TCAACCCTGTGCCATCAGTA 515 58.6 
*Size of amplicon (bp, base pairs) 
†Annealing temperatures used for amplification of exons 
‡Two overlapping primer pairs were used to amplify exon 13.	  
Table 2. P2RX7 genotype and P2X7 function of dogs 
 
P2RX7 Genotype* P2X7 
Breed F103L R270C R365Q P452S Function† 
Alaskan Malamute WT WT WT P/S 192 
Alaskan Malamute  WT WT WT P/S 263 
Alaskan Malamute and Siberian Husky cross 
 
WT WT P/S 187 
American Staffordshire Terrier F/L WT WT WT 195 
American Staffordshire Terrier F/L WT WT P/S 85 
American Staffordshire Terrier L/L WT WT WT 77 
Australian Bulldog L/L WT WT WT 207 
Australian Cattle Dog F/L WT WT P/S 282 
Australian Kelpie 
 
WT WT P/S 173 
Basenji WT WT WT WT 258 
Beagle WT WT WT WT 
 Beagle WT WT WT S/S 165 
Border Collie WT WT WT P/S 149 
Boarder Collie and Australian Cattle Dog cross WT WT WT WT 395 
Bull Terrier L/L WT WT WT 
 Bull Terrier cross F/L WT WT WT 256 
Bull Terrier (Miniature) L/L WT WT WT 165 
Cavalier King Charles Spaniel WT WT WT S/S 129 
Cavalier King Charles Spaniel and Cocker Spaniel cross WT R/C WT S/S 44 
Chihuahua and Dachshund (Miniature) cross F/L WT WT WT 130 
Corgi cross F/L WT WT P/S 
 Dachshund WT WT WT 
  Dachshund WT 
  
WT 
 Dachshund (Miniature) WT WT WT S/S 82 
Dachshund (Miniature) WT WT WT S/S 129 
Dachshund (Miniature) 
 
WT WT S/S 168 
Dachshund (Miniature) L/L WT WT S/S 30 
Fox Terrier (Miniature) WT WT WT P/S 
 Fox Terrier (Miniature) F/L WT WT P/S 123 
German Shorthaired Pointer WT WT WT S/S 
 Golden Retriever WT WT WT P/S 153 
Golden Retriever and Labrador Retriever cross L/L WT R/Q WT 31 
Jack Russell Terrier WT WT WT P/S 106 
Jack Russell Terrier L/L WT WT WT 32 
Jack Russell Terrier cross L/L WT WT WT 
 Jack Russell Terrier cross L/L WT WT WT 
 Labrador Retriever WT WT WT WT 152 
Labrador Retriever WT WT WT P/S 21 
Labrador Retriever WT WT WT P/S 272 
Labrador Retriever WT WT R/Q P/S  
Labrador Retriever WT WT R/Q P/S 80 
Labrador Retriever 
 
WT R/Q S/S 196 
Maltese WT WT WT WT 58 
Maltese cross F/L WT WT 
  Maltese and Poodle cross F/L 
  
WT 
 Maltese and Shih Tzu cross WT WT WT P/S 126 
Maltese and Shih Tzu cross WT WT WT P/S 208 
Maltese and Shih Tzu cross WT WT WT S/S 246 
Mastiff and American Staffordshire Bull Terrier cross L/L WT WT WT 64 
Poodle and Cocker Spaniel cross WT WT WT S/S 
 Pug and Beagle cross L/L WT WT S/S 35 
Pug and Fox Terrier cross 
    
49 
Pug and Pomeranian cross F/L WT WT P/S 80 
Rhodesian Ridgeback WT WT WT P/S 236 
Rhodesian Ridgeback and Australian Cattle Dog cross WT WT WT 
  Schnauzer (Miniature) and Bulldog cross F/L WT WT P/S 88 
Schnauzer (Miniature) and Bulldog cross L/L WT WT WT 122 
Shar Pei WT WT WT P/S 337 
Siberian Husky  WT WT WT P/S 25 
Siberian Husky  WT WT WT P/S 466 
Staffordshire Bull Terrier L/L WT WT WT 
 Staffordshire Bull Terrier L/L WT WT WT 
 Staffordshire Bull Terrier L/L WT WT WT 64 
Staffordshire Bull Terrier L/L WT WT WT 165 
Staffordshire Bull Terrier L/L WT WT WT 146 
Staffordshire Bull Terrier cross 
 
WT WT WT 198 
Staffordshire Bull Terrier cross F/L WT WT P/S 
 Staffordshire Bull Terrier cross F/L WT WT P/S 223 
Staffordshire Bull Terrier cross L/L WT WT P/S 39 
MDCK cells (Cocker Spaniel) WT R/C WT P/S 0 
*P2RX7 genotype was determined by sequencing of genomic DNA. 










     F103L     N131N     R270C     R365Q     L440F     P452S 
       |         |         |         |         |         | 
Canine, NCBI ∙∙∙NSFFVMT∙∙∙LCSNDWG∙∙∙HHCRPKY∙∙∙KCCRSHI∙∙∙LSRLSLS∙∙∙DLSPIPG∙∙∙ 
Canine, Boxer ∙∙∙NSFLVMT∙∙∙LCSNDWG∙∙∙HHCRPKY∙∙∙KCCRSHI∙∙∙LSRLSLS∙∙∙DLSPIPG∙∙∙ 
Canine, GSK ∙∙∙NSFLVMT∙∙∙LCSNDWG∙∙∙HHCRPKY∙∙∙KCCRSHI∙∙∙LSRLSLS∙∙∙DLSPIPG∙∙∙ 
Canine, EES ∙∙∙NSFFVMT∙∙∙LCSNDWG∙∙∙HHCRPKY∙∙∙KCCRSHI∙∙∙LSRFSLS∙∙∙DLSSIPG∙∙∙ 
Human ∙∙∙NSFFVMT∙∙∙LCSSDRG∙∙∙HHCRPKY∙∙∙NCCRSHI∙∙∙LSRLPLA∙∙∙DTPPIPG∙∙∙ 
Rhesus Macaque ∙∙∙NSFFVMT∙∙∙LCSSDRG∙∙∙HHCRPKY∙∙∙NYCRSHI∙∙∙LSKLPLA∙∙∙DPPPIPG∙∙∙ 
Rat ∙∙∙NSFFVMT∙∙∙QCHSDQG∙∙∙HRCQPKY∙∙∙TCCRSRV∙∙∙LSRLSLS∙∙∙HSPPIPG∙∙∙ 
Mouse ∙∙∙NSFFVMT∙∙∙QCSSDRR∙∙∙HHCRPKY∙∙∙AFCRSGV∙∙∙LSRLSLS∙∙∙DSPPTPG∙∙∙ 
 
